https://www.caplytahcp.com/component---src-pages-schizophrenia-pro…-subscale-index-jsx-4e88d8d52f270a9b14e6.js

1"use strict";(self.webpackChunkedge_itci_caplyta_hcp_combo_rebuild=self.webpackChunkedge_itci_caplyta_hcp_combo_rebuild||[]).push([[359],{25052:function(e,t,a){a.d(t,{A:function(){return s}});var l=a(96540),n=a(86462),c=a(64016);var r=function(e){return void 0===e&&(e=!1),l.createElement(l.Fragment,null,e?l.createElement("svg",{xmlns:"http://www.w3.org/2000/svg",width:"24",height:"25",viewBox:"0 0 24 25",fill:"none"},l.createElement("circle",{cx:"12",cy:"12.1847",r:"11",stroke:"#FF5A57",strokeWidth:"2"}),l.createElement("path",{d:"M12 6.18469V18.1847",stroke:"#FF5A57",strokeWidth:"2",strokeLinecap:"round",strokeLinejoin:"round"}),l.createElement("path",{d:"M6 12.1847H18",stroke:"#FF5A57",strokeWidth:"2",strokeLinecap:"round",strokeLinejoin:"round"})):l.createElement("svg",{width:"32",height:"31",viewBox:"0 0 32 31",fill:"none",xmlns:"http://www.w3.org/2000/svg"},l.createElement("circle",{cx:"15.7389",cy:"15.4671",r:"15.3756",fill:"#885B95"}),l.createElement("path",{d:"M6.60547 15.467H24.8711",stroke:"white",strokeWidth:"3",strokeLinecap:"round"}),l.createElement("path",{d:"M15.7383 6.33423L15.7383 24.5999",stroke:"white",strokeWidth:"3",strokeLinecap:"round"})))};var s=e=>{const t=e.id,a=void 0===t?"":t,s=e.className,o=void 0===s?"":s,i=e.anchorId,m=void 0===i?"":i,d=e.initialExpanded,p=void 0!==d&&d,u=e.headingLevel,E=void 0===u?3:u,g=e.collapsedLabel,b=e.expandedLabel,f=e.children,N=e.altIcon,h=void 0!==N&&N,A=(0,n.useLocation)().hash,v=(0,l.useRef)(null),x=(0,l.useRef)(null),w=(0,l.useRef)(null),y=(0,l.useState)(p),k=y[0],S=y[1],T=a+"__button",C=a+"__panel",L="h"+E,P=()=>{var e;S(!0),null==w||null===(e=w.current)||void 0===e||e.focus()},H=()=>{var e;S(!1),null==x||null===(e=x.current)||void 0===e||e.focus()},I=e=>(e.preventDefault(),c.A.toggleAccordion(k),document.dispatchEvent(new CustomEvent("accordionToggle",{bubbles:!0,detail:{isOpen:!k}})),k?H():P()),F=e=>{var t;e.detail.accordionId===(null==v||null===(t=v.current)||void 0===t?void 0:t.id)&&I(e)},B=e=>{var t;e.detail.accordionId===(null==v||null===(t=v.current)||void 0===t?void 0:t.id)&&P()},O=e=>{var t;e.detail.accordionId===(null==v||null===(t=v.current)||void 0===t?void 0:t.id)&&H()};return(0,l.useEffect)(()=>(document.addEventListener("accordionToggle",F),document.addEventListener("accordionOpen",B),document.addEventListener("accordionClose",O),()=>{document.removeEventListener("accordionToggle",F),document.removeEventListener("accordionOpen",B),document.removeEventListener("accordionClose",O)}),[k]),(0,l.useEffect)(()=>{const e=()=>{if(A){const e=A.slice(1);m.includes(e)&&(P(),setTimeout(()=>{v.current.scrollIntoView({behavior:"smooth"})},100))}};return e(),window.addEventListener("hashchange",e),()=>{window.removeEventListener("hashchange",e)}},[A]),l.createElement("div",{id:a,className:"kf-accordion "+o,ref:v},l.createElement(L,{id:m,className:"kf-accordion__trigger"},l.createElement("button",{ref:x,id:T,className:"kf-accordion__button "+(k?"expanded":""),"aria-expanded":k?"true":"false","aria-controls":C,onClick:I},k&&b||g,l.createElement(r,{alt:h}))),l.createElement("div",{ref:w,id:C,className:"kf-accordion__panel "+(k?"expanded":""),role:"region","aria-labelledby":T,"aria-hidden":k?"false":"true"},f))}},34042:function(e,t,a){var l=a(98587),n=a(96540);const c=["children","className","swipeText","mobileOnly","scrollAmount"];t.A=e=>{let t=e.children,a=e.className,r=e.swipeText,s=void 0===r?"swipe left to see more":r,o=e.mobileOnly,i=void 0===o||o,m=e.scrollAmount,d=void 0===m?200:m,p=(0,l.A)(e,c);const u=(0,n.useRef)(null),E=(0,n.useState)(!1),g=E[0],b=E[1],f=(0,n.useState)(!0),N=f[0],h=f[1],A=(0,n.useCallback)(()=>{if(!u.current)return;const e=u.current,t=e.scrollLeft,a=e.scrollWidth,l=e.clientWidth;b(t>0),h(t<a-l-1)},[]),v=e=>{if(!u.current)return;const t=u.current,a=t.scrollLeft,l=t.clientWidth,n=t.scrollWidth;if("right"===e){const e=a+d;e>=n-l?t.scrollTo({left:n-l,behavior:"smooth"}):t.scrollTo({left:e,behavior:"smooth"})}else{const e=a-d;e<=0?t.scrollTo({left:0,behavior:"smooth"}):t.scrollTo({left:e,behavior:"smooth"})}};return(0,n.useEffect)(()=>{const e=u.current;if(e){e.addEventListener("scroll",A),A();const t=new IntersectionObserver(e=>

1{e.forEach(e=>{e.isIntersecting&&A()})},{threshold:.01});t.observe(e);const a=new ResizeObserver(()=>{A()});a.observe(e);const l=()=>A();return window.addEventListener("resize",l),()=>{e.removeEventListener("scroll",A),t.disconnect(),a.disconnect(),window.removeEventListener("resize",l)}}},[A]),n.createElement("div",Object.assign({className:"scrollable-wrapper "+(i?"scroll-mobile-only":"")+" "+(a||"")+" "+(g?"show-left-arrow":"")+" "+(N?"show-right-arrow":"")},p),s&&n.createElement("p",{className:"scroll-table-text"},n.createElement("span",{className:"swipe-text"},n.createElement("button",{className:"scroll-button scroll-left",onClick:()=>v("left"),"aria-label":"Scroll left",disabled:!g,tabIndex:g?0:-1}),s,n.createElement("button",{className:"scroll-button scroll-right",onClick:()=>v("right"),"aria-label":"Scroll right",disabled:!N,tabIndex:N?0:-1}))),n.createElement("div",{ref:u,"data-kfs":"scrollable-wrapper",className:"content-wrapper"},t))}},43914:function(e,t,a){var l=a(96540);t.A=e=>{let t=e.title,a=e.children,n=e.scrollableOnMobile,c=void 0!==n&&n,r=e.className,s=void 0===r?"":r;return l.createElement("div",{className:"circle-title-box "+(c?"scrollable-on-mobile":"")+" "+s},l.createElement("div",{className:"circle-title-box__inner"},l.createElement("div",{className:"circle-title-box__title-flex"},l.createElement("div",{className:"circle-title-box__title"},l.createElement("div",{className:"circle-title-box__title-inner"},l.createElement("span",null,t)))),l.createElement("div",{className:"circle-title-box__content"},a)))}},60991:function(e,t,a){a.d(t,{A:function(){return i}});var l=a(96540),n=a(14536),c=a.p+"static/hero-mdd--desktop-cac88e7fa5ad577416958e4aaf8a1058.png",r=a.p+"static/hero-mdd--about-mdd-desktop-6a50c771c361acc8bf2a329ac37da4c4.png",s=a.p+"static/hero-mdd--desktop-2lines-b9acb400aa52f3327d621a3f02012961.png",o=a.p+"static/hero-mdd--desktop-3lines-c179daba3aecfb1c645fa77f8e1ec20f.png";var i=e=>{const t=e.title,a=e.anchorLinks,i=e.className,m=void 0===i?"":i,d=e.eyebrow,p=e.hideTorchBG,u=void 0!==p&&p,E=e.heroCopyLines,g=void 0===E?1:E;let b="";return b=u?r:g?{1:c,2:s,3:o}[g]:c,l.createElement("section",{className:"hero-mdd "+m},l.createElement("div",{className:"hero-inner"},l.createElement("div",{className:"hero-bg"},l.createElement("img",{src:b,alt:"",className:"hero-bg--img hidden lg:block "+(3===g?"xl4:hidden":2===g&&"4xl:hidden")}),3===g&&l.createElement("img",{src:s,alt:"",className:"hero-bg--img hidden xl4:block 4xl:hidden"}),l.createElement("img",{src:c,alt:"",className:"hero-bg--img hidden 4xl:block"})),l.createElement("div",{className:"hero-bg-mobile-wrapper"},l.createElement("img",{src:"data:image/png;base64,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",alt:"",className:"hero-bg--orange-mobile"})),l.createElement("div",{className:"hero-content container"},l.createElement("h1",{className:"hero-title"},d&&l.createElement("span",{className:"hero-title--eyebrow"},d),l.createElement("span",{className:"hero-title--title"},t)))),a&&l.createElement("div",{className:"extra-side-padding 2xl:max-w-[100rem] 4xl:max-w-[110rem]"},l.createElement("div",{className:"container flex flex-col items-center gap-3 xl:flex-row xl:gap-5"},l.createElement("p",{className:"hero-anchor-links--title"},"Jump To:"),l.createElement("div",{className:"hero-anchor-links"},a.map((e,t)=>l.createElement("button",{key:t,onClick:()=>{(0,n.YJ)(e.target,!0)}},e.ctaCopy))))))}},65224:function(e,t,a){a.d(t,{A:function(){return m}});var l=a(96540),n=a(64810),c=a.p+"static/bg-crosslink-desktop-1920-a4b16dbb0009d494db32fc08dc779948.png",r=a.p+"static/bg-crosslink-desktop-1536-79dfae119910a98b0bc405216265fb11.png",s=a.p+"static/bg-crosslink-desktop-beefe0640988cea8f21841b12e923f0f.png",o=a.p+"static/bg-crosslink-mobile-9946e7c1335b64492bf4ab56be917e1b.png";const i=e=>

1{let t=e.circleColor,a=void 0===t?"white":t,n=e.arrowColor,c=void 0===n?"#FF5A57":n;return l.createElement("svg",{width:"40",height:"41",viewBox:"0 0 40 41",fill:"none",xmlns:"http://www.w3.org/2000/svg",className:"crosslink-arrow"},l.createElement("circle",{cx:"20",cy:"20.0276",r:"19",fill:a,stroke:a,strokeWidth:"2"}),l.createElement("path",{d:"M19.6846 12.6539C20.0751 12.2635 20.7082 12.2634 21.0986 12.6539L28.1562 19.7115C28.2191 19.7744 28.2709 19.8441 28.3135 19.9176C28.3361 19.9566 28.3557 19.9975 28.373 20.0396C28.4357 20.1928 28.4599 20.3578 28.4434 20.5201C28.4282 20.6708 28.3783 20.8108 28.3037 20.9342C28.2628 21.0019 28.2147 21.0671 28.1562 21.1256L21.0986 28.1842C20.7083 28.5743 20.0751 28.574 19.6846 28.1842C19.294 27.7936 19.294 27.1597 19.6846 26.7691L25.0352 21.4185H13.333C12.7809 21.4184 12.333 20.9707 12.333 20.4185C12.3331 19.8664 12.7809 19.4187 13.333 19.4185H25.0352L19.6846 14.068C19.294 13.6774 19.294 13.0444 19.6846 12.6539Z",fill:c}))};var m=e=>{const t=e.ctaCopy,a=e.ctaLink;return l.createElement("section",{className:"crosslink-mdd"},l.createElement("div",{className:"crosslink-mdd-bg"},l.createElement("img",{src:c,alt:"",className:"crosslink-mdd-bg-img desktop-1920-only"}),l.createElement("img",{src:r,alt:"",className:"crosslink-mdd-bg-img desktop-1536-only"}),l.createElement("img",{src:s,alt:"",className:"crosslink-mdd-bg-img desktop-tablet-only"}),l.createElement("img",{src:o,alt:"",className:"crosslink-mdd-bg-img mobile-only"})),l.createElement("div",{className:"container crosslink-inner"},l.createElement("div",{className:"crosslink-mdd-btn"},l.createElement(n.N_,{to:a},l.createElement("span",null,t),l.createElement(i,null)))))}},71845:function(e,t,a){a.r(t),a.d(t,{Head:function(){return u},default:function(){return p}});var l=a(96540),n=a(3314),c=a(60991),r=a(40973),s=a(25052),o=a(43914),i=a(65224),m=a(34042),d=a.p+"static/subscale-4-week-graph-cb9468f91c28cf4704b558c870c1376d.svg";var p=()=>{const e=l.createElement(l.Fragment,null,l.createElement("b",null,"1"),". Lieberman JA, Davis RE, Correll CU, et al. ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. ",l.createElement("i",null,"Biol Psychiatry"),". 2016,79(12):952-961. doi:10.1016/ j.biopsych.2015.08.026 ",l.createElement("b",null,"2"),". CAPLYTA Prescribing Information. ",l.createElement("b",null,"3"),". Data on File (REF-02886, REF-02887). ",l.createElement("b",null,"4.")," Correll CU, David RE, Weingart M, et al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. ",l.createElement("i",null,"JAMA Psychiatry"),". 2020;77(4):349-358. doi:10.1001/jamapsychiatry.2019.4379 ",l.createElement("b",null,"5"),". Shankar G, Nate C. Positive and Negative Syndrome Scale as a long-term outcome measurement tool in patients receiving clozapine ODT- A Pilot Study. ",l.createElement("i",null,"Pharm Pract (Granada)"),". 2007;5(1):42-45.");return l.createElement(l.Fragment,null,l.createElement(n.A,{className:"page--prosocial-subscale-scz",references:e},l.createElement(c.A,{heroCopyLines:2,eyebrow:l.createElement(l.Fragment,null,"For SCHIZOPHRENIA in adults"),title:l.createElement(l.Fragment,null,"Observed reductions in PANSS symptom domains in patients on CAPLYTA",l.createElement("sup",null,"1"))}),l.createElement("div",{className:"page--content"},l.createElement("div",{className:"container scrollable-wrapper-long-term-data"},l.createElement(m.A,{swipeText:"Swipe chart for more"},l.createElement(o.A,{title:l.createElement(l.Fragment,null,"Change from baseline in PANSS",l.createElement("br",{className:"mobile-only"})," subscale scores at 4 weeks",l.createElement("sup",null,"1")),scrollableOnMobile:!0,className:"mr-7 lg:mr-0"},l.createElement("div",{className:"madrs-total-score-graph mt-[-4rem] lg:mt-[-3rem]"},l.createElement("img",{src:d,alt:"This line graph shows changes in MADRS total scores over time from baseline through 26 weeks for patients receiving CAPLYTA 42 mg or placebo.",className:"madrs-total-score-graph-img mx-auto"}))))),l.createElement("div",{className:"container"},l.createElement("section",null,l.createElement("p",{className:"text-base font-roboto-condensed font-bold leading-[20px] mt-4"},"Limitation: These secondary endpoint and exploratory post hoc analyses were not powered for statistical comparison and are descriptive only; results require cautious interpretation."),l.createElement("p",{className:"text-[13px] mt-5 leading-[1.25] pr-2 font-roboto-condensed font-medium"},"Baseline PANSS Total Scores: CAPLYTA 42 mg: 88.1; placebo: 86.3.",l.createElement("sup",null,"1")),l.createElement("p",{className:"text-[13px] mt-1 leading-[1.25] font-roboto-condensed font-medium"},"LSM=least squares mean; PANSS=Positive and Negative Syndrome Scale.")),l.createElement("section",null,l.createElement(s.A,{id:"phq-9-equivalents",className:"accordion-item accordion-mdd mt-11",anchorId:"study-design",collapsedLabel:"View study design",expandedLabel:"Hide study design",altIcon:!0},l.createElement("h3",{className:"text-lg text-blue text-center font-bold leading-[1.25]"},"CAPLYTA was evaluated in two randomized, multicenter, double-blind placebo-controlled studies",l.createElement("sup",null,"1-4")),l.createElement("div",{className:"twin-flow-chart mt-6 lg:mt-[48px] mb-10"},l.createElement(o.A,{title:l.createElement(l.Fragment,null,"Study 1 (N=335)"),className:""},l.createElement("div",{className:"flow-content"},l.createElement("div",{className:"screening-section"},l.createElement("p",{className:"screening-title-mobile"},l.createElement("strong",null,"SCREENING PHASE"),l.createElement("br",null),"Up to 7 days"),l.createElement("div",{className:"screening-box"},l.createElement("p",{className:"screening-title-desktop left-section-title"},l.createElement("strong",null,"SCREENING PHASE"),l.createElement("br",null),"Up to 7 days"),l.createElement("ul",null,l.createElement("li",null,"Patients were 20–55 years old (median age: 42 years)"),l.createElement("li",null,"Had acute exacerbation of schizophrenia and were generally moderately to markedly ill"))),l.createElement("span",{className:"chart-connector"})),l.createElement("div",{className:"treatment-section"},l.createElement("div",{className:"treatment-title-mobile"},l.createElement("p",{className:"title"},l.createElement("strong",null,"TREATMENT PHASE")," 4 weeks"),l.createElement("p",{className:"subtitle"},"Randomized 1:1:1:1")),l.createElement("span",{className:"chart-curve-connector"}),l.createElement("div",{className:"treatment-options"},l.createElement("div",{className:"btn-blue"},l.createElement("span",null,"Oral CAPLYTA",l.createElement("br",null),"42 mg ",l.createElement("strong",null,"or")," 84 mg")),l.createElement("div",{className:"btn-with-border relative lg:before:content-[attr(before)] lg:before:absolute lg:before:right-[100%] lg:before:bg-[#FF5A57] lg:before:w-[32px] lg:before:h-[2px]"},"Risperidone 4 mg",l.createElement("br",null),"(assay sensitivity)"),l.createElement("div",{className:"btn-grey"},"Placebo"),l.createElement("div",{className:"treatment-title-desktop"},l.createElement("p",{className:"title"},l.createElement("strong",null,"TREATMENT PHASE")," 4 weeks"),l.createElement("p",{className:"subtitle"},"Randomized 1:1:1:1")))))),l.createElement(o.A,{title:l.createElement(l.Fragment,null,"Study 2 (N=450)"),className:"chart-2"},l.createElement("div",{className:"flow-content"},l.createElement("div",{className:"screening-section"},l.createElement("p",{className:"screening-title-mobile"},l.createElement("strong",null,"SCREENING PHASE"),l.createElement("br",null),"Up to 7 days"),l.createElement("div",{className:"screening-box"},l.createElement("p",{className:"screening-title-desktop left-section-title"},l.createElement("strong",null,"SCREENING PHASE"),l.createElement("br",null),"Up to 7 days"),l.createElement("ul",null,l.createElement("li",null,"Patients were 19–60 years old (median age: 44 years)"),l.createElement("li",null,"Had acute exacerbation of schizophrenia and were generally moderately to markedly ill"))),l.createElement("span",{className:"chart-connector"})),l.createElement("div",{className:"treatment-section"},l.createElement("div",{className:"treatment-title-mobile"},l.createElement("p",{className:"title"},l.createElement("strong",null,"TREATMENT PHASE")," 4 weeks"),l.createElement("p",{className:"subtitle"},"Randomized 1:1:1")),l.createElement("span",{className:"chart-curve-connector"}),l.createElement("div",{className:"treatment-options"},l.createElement("div",{className:"btn-blue"},l.createElement("span",null,"Oral CAPLYTA",l.createElement("br",null),"28 mg ",l.createElement("strong",null,"or")," 42 mg")),l.createElement("div",{className:"btn-grey"},"Placebo"),l.createElement("div",{className:"treatment-title-desktop"},l.createElement("p",{className:"title"},l.createElement("strong",null,"TREATMENT PHASE")," 4 weeks"),l.createElement("p",{className:"subtitle"},"Randomized 1:1:1"))))))),l.createElement("div",{className:"px-8 py-4 text-center bg-purple roun

1ded-2xl mt-5"},l.createElement("p",{className:"text-xl font-bold font-roboto-condensed text-white leading-[24px]"},"Primary endpoint was change from baseline in the PANSS total score at 4 weeks")),l.createElement("p",{className:"text-[15px] leading-[16px] font-roboto-condensed font-medium mt-5 lg:mt-10 lg:mb-0 pr-2"},"In both studies, the treatment effect in the CAPLYTA 84 mg group (vs placebo) and CAPLYTA 28 mg group (vs placebo) was not statistically significant."))),l.createElement("section",null,l.createElement("h3",{className:"text-[28px] lg:text-[32px] text-blue leading-[1] font-roboto-condensed font-bold mt-14 pr-[10px] md:pr-0 tracking-[-0.5px] mb-7 lg:mb-8"},"The PANSS is a 30-item scale that measures the following symptoms",l.createElement("sup",null,"1,2,5"),"*:"),l.createElement("div",{className:"lg:flex lg:justify-between gap-5"},l.createElement("div",{className:"flex-1"},l.createElement("p",{className:"text-2xl font-roboto leading-[22px] font-bold text-blue pr-4"},"Positive Subscale Symptoms:"),l.createElement("ul",{className:"font-roboto list-disc pl-5 marker:text-blue text-lg leading-[22px]"},l.createElement("li",{className:"mt-3"},"Delusions"),l.createElement("li",{className:"mt-[6px]"},"Hallucinations"),l.createElement("li",{className:"mt-[6px]"},"Conceptual disorganization"),l.createElement("li",{className:"mt-[6px]"},"Excitement"),l.createElement("li",{className:"mt-[6px]"},"Grandiosity"),l.createElement("li",{className:"mt-[6px]"},"Suspiciousness/persecution"),l.createElement("li",{className:"mt-[6px]"},"Hostility"))),l.createElement("div",{className:"flex-1"},l.createElement("p",{className:"text-2xl font-roboto leading-[22px] font-bold text-blue pr-4"},"Negative Subscale Symptoms:"),l.createElement("ul",{className:"font-roboto list-disc pl-5 marker:text-blue text-lg leading-[22px]"},l.createElement("li",{className:"mt-3"},"Blunted affect"),l.createElement("li",{className:"mt-[6px]"},"Emotional withdrawal"),l.createElement("li",{className:"mt-[6px]"},"Poor rapport"),l.createElement("li",{className:"mt-[6px]"},"Passive/apathetic social withdrawal"),l.createElement("li",{className:"mt-[6px]"},"Difficulty in abstract thinking"),l.createElement("li",{className:"mt-[6px]"},"Lack of spontaneity and flow of conversation"),l.createElement("li",{className:"mt-[6px]"},"Stereotyped thinking")))),l.createElement("p",{className:"text-2xl font-roboto leading-[22px] font-bold text-blue mt-4"},"General Psychopathology Subscale Symptoms:"),l.createElement("div",{className:"lg:flex"},l.createElement("ul",{className:"font-roboto list-disc pl-5 marker:text-blue text-lg leading-[22px] flex-1"},l.createElement("li",{className:"mt-4"},"Somatic concern"),l.createElement("li",{className:"mt-[6px]"},"Anxiety"),l.createElement("li",{className:"mt-[6px]"},"Guilt feelings"),l.createElement("li",{className:"mt-[6px]"},"Tension"),l.createElement("li",{className:"mt-[6px]"},"Mannerisms and posturing"),l.createElement("li",{className:"mt-[6px]"},"Depression"),l.createElement("li",{className:"mt-[6px]"},"Motor retardation"),l.createElement("li",{className:"mt-[6px]"},"Uncooperativeness")),l.createElement("ul",{className:"font-roboto list-disc pl-5 marker:text-blue text-lg leading-[22px] flex-1"},l.createElement("li",{className:"mt-4"},"Unusual thought content"),l.createElement("li",{className:"mt-[6px]"},"Disorientation"),l.createElement("li",{className:"mt-[6px]"},"Poor attention"),l.createElement("li",{className:"mt-[6px]"},"Lack of judgement and insight"),l.createElement("li",{className:"mt-[6px]"},"Disturbance of volition"),l.createElement("li",{className:"mt-[6px]"},"Poor impulse control"),l.createElement("li",{className:"mt-[6px]"},"Preoccupation"),l.createElement("li",{className:"mt-[6px]"},"Active social avoidance"))),l.createElement("p",{className:"text-2xl font-roboto leading-[22px] font-bold text-blue mt-4"},"PANSS Prosocial Subscale"),l.createElement("p",{className:"text-lg font-roboto leading-[22px] mt-4"},"The PANSS Prosocial Subscale is a 6-item scale derived from the PANSS total score to measure social functioning. It includes the following symptoms:"),l.createElement("div",{className:"lg:flex"},l.createElement("ul",{className:"font-roboto list-disc pl-5 marker:text-blue text-lg leading-[22px] flex-1"},l.createElement("li",{className:"mt-[6px]"},"Hallucinations"),l.createElement("li",{className:"mt-[6px]"},"Suspiciousness/persecution"),l.createElement("li",{className:"mt-[6px]"},"Emotional withdrawal")),l.createElement("ul",{className:"font-roboto list-disc pl-5 marker:text-blue text-lg leading-[22px] flex-1"},l.createElement("li",{className:"mt-[6px]"},"Passive/apathetic social withdrawal"),l.createElement("li",{className:"mt-[6px]"},"Stereotyped thinking"),l.createElement("li",{className:"mt-[6px]"},"Active social avoidance"))),l.createElement("p",{className:"text-[13px] lg:text-sm font-medium leading-[1.25] mt-16 sup--outside font-roboto-condensed lg:pr-10"},l.createElement("span",null,"*"),"Each item is rated by a clinician on a 7-point scale. A score of 1 indicates the absence of symptoms, and a score of 7 indicates extremely severe symptoms. The PANSS total score may range from 30 to 210, with higher scores reflecting greater overall symptom severity.",l.createElement("sup",null,"2,5")),l.createElement("p",{className:"text-[13px] lg:text-sm font-medium leading-[1.25] mt-1 lg:mt-[6px] mb-14 lg:mb-16 font-roboto-condensed"},"PANSS=Positive and Negative Syndrome Scale."))),l.createElement(i.A,{ctaCopy:l.createElement(l.Fragment,null,"See the well-established safety and tolerability profile for CAPLYTA"),ctaLink:"/schizophrenia/eps-akathisia"}))))};const u=()=>l.createElement(r.A,{title:"Prosocial Subscale - Schizophrenia | CAPLYTA® (lumateperone)",description:"View a post hoc analysis of CAPLYTA on changes in prosocial symptom domain scores in schizophrenia. Please see full Prescribing Information, including Boxed WARNINGS."})}}]);
2//# sourceMappingURL=component---src-pages-schizophrenia-prosocial-subscale-index-jsx-4e88d8d52f270a9b14e6.js.map